Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies

Bonum Therapeutics, a biopharmaceutical company using allosteric regulation to create conditionally active and less toxic medicines, announced a $93M Series A financing. Bonum is developing new therapies based on the proprietary platform of allosterically regulated, conditionally active therapeutics developed by Good Therapeutics. The value of the platform was validated by the Roche acquisition of Good Therapeutics and its PD-1 regulated IL-2 program.

Bonum is a spinout of Good Therapeutics, which Roche acquired in August 2022 for $250M upfront plus potential milestone payments. The core platform makes possible the engineering and development of a broad array of important medicines. The Series A financing will allow Bonum to apply the technology to regulated cytokines, including IL-12, IFN-alpha, and TGF-beta for immuno-oncology applications. In parallel, Bonum will seek collaborators for application of its technology in other disease areas.